vimarsana.com

Latest Breaking News On - Carold karp - Page 1 : vimarsana.com

Penserra Capital Management LLC Makes New $211,000 Investment in Prothena Co. plc (NASDAQ:PRTA)

Penserra Capital Management LLC bought a new position in shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,104 shares of the biotechnology company’s stock, valued at approximately $211,000. Several other […]

United-states
Hideki-garren
Carold-karp
Northern-trust-corp
Osaic-holdings-inc
Cantor-fitzgerald
Moran-wealth-management
Nasdaq
Prothena-corporation
Prothena-co
Prothena-company-profile
Proshare-advisors

StockNews.com Downgrades Prothena (NASDAQ:PRTA) to Sell

Prothena (NASDAQ:PRTA – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Monday. A number of other analysts have also commented on PRTA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $129.00 price target on shares of Prothena in a […]

United-states
Arizona
American
Carold-karp
Hideki-garren
Prothena-corporation
Cantor-fitzgerald
Prothena-company-profile
Securities-exchange-commission
American-international-group-inc
Ameritas-investment-partners-inc
Guggenheim-capital

Prothena Co. plc (NASDAQ:PRTA) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Prothena Co. plc (NASDAQ:PRTA – Free Report) have received a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month […]

United-states
Wellington
New-zealand-general
New-zealand
America
Brandons-smith
Carold-karp
Prothena-company-profile
Prothena-corporation
Nasdaq
Securities-exchange-commission

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.